021-51111890
购物车（）
sales@molnova.cn
4-Hydroxytamoxifen
CAS No. 68392-35-8
4-Hydroxytamoxifen ( Afimoxifene )
产品货号. M15614 CAS No. 68392-35-8
A selective estrogen receptor modulator (SERM) and the major active metabolite of tamoxifen.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥381 | 有现货 |
|
| 10MG | ￥583 | 有现货 |
|
| 25MG | ￥1045 | 有现货 |
|
| 50MG | ￥1725 | 有现货 |
|
| 100MG | ￥2657 | 有现货 |
|
| 200MG | ￥3993 | 有现货 |
|
| 500MG | ￥6391 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称4-Hydroxytamoxifen
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A selective estrogen receptor modulator (SERM) and the major active metabolite of tamoxifen.
-
产品描述A selective estrogen receptor modulator (SERM) and the major active metabolite of tamoxifen; exhibits more potent estrogen agonist/antagonist activity and can inhibit MCF-7 and MDA-MB-231 cell proliferation with IC50 values of 27 and 18 uM, respectively.Breast Cancer Phase 2 Clinical
-
同义词Afimoxifene
-
通路Endocrinology/Hormones
-
靶点Estrogen Receptor/ERR
-
受体Others
-
研究领域Cancer
-
适应症Breast Cancer
化学信息
-
CAS Number68392-35-8
-
分子量387.51
-
分子式C26H29NO2
-
纯度>98% (HPLC)
-
溶解度DMSO: 71 mg/mL (183.2 mM); Ethanol: <1 mg/mL; Water: <1 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESOC1=CC=C(/C(C2=CC=C(OCCN(C)C)C=C2)=C(C3=CC=CC=C3)/CC)C=C1
-
化学全称(Z)-4-(1-(4-(2-aminoethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Mansel R, et al. Breast Cancer Res Treat. 2007 Dec;106(3):389-97.
2. Desta Z, et al. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
3. Seeger H, et al. Horm Metab Res. 2004 May;36(5):277-80.
2. Desta Z, et al. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
3. Seeger H, et al. Horm Metab Res. 2004 May;36(5):277-80.
产品手册
关联产品
-
Mestranol
Mestranol is the 3-methyl ether of ethinylestradiol. It was the estrogen used in many of the first oral contraceptives.
-
Pimaricin
Natamycin is a Polyene Antimicrobial.
-
Toremifene
Toremifene (NK 622; FC 1157a) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis.
